Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Eur J Neurosci. 2012 Jan 25;35(3-4):562–571. doi: 10.1111/j.1460-9568.2011.07972.x

Figure 2. p66-KO mice showed less severe clinical EAE compared to WT mice.

Figure 2

Immunized p66-KO and WT mice were scored daily for clinical signs of weakness and paralysis over a 36-day observation period. Throughout the entire clinical course, mean p66-KO scores were less than the WT scores. At the end of the 36 days, the p66-KO mice had significantly lower scores compared to the WT mice, reflecting the overall trend of reduced clinical impairment.